Somatostatin receptor-targeted organometallic iridium(III) complexes as novel theranostic agents

Novohradsky, Vojtech; Zamora, Ana; Gandioso, Albert; Brabec, Viktor; Ruiz, José; Marchan, Vicente

RICSMUR Principal
→
03. IMIB (Instituto Murciano de Investigación Biosanitaria Pascual Parrilla)
→
03.01. Investigación y comunicación científica
→
Ver ítem

dc.contributor.author	Novohradsky, Vojtech
dc.contributor.author	Zamora, Ana
dc.contributor.author	Gandioso, Albert
dc.contributor.author	Brabec, Viktor
dc.contributor.author	Ruiz, José
dc.contributor.author	Marchan, Vicente
dc.date.accessioned	2026-01-22T07:31:42Z
dc.date.available	2026-01-22T07:31:42Z
dc.date.issued	2017-05-18
dc.identifier.citation	Novohradsky V, Zamora A, Gandioso A, Brabec V, Ruiz J, Marchán V. Somatostatin receptor-targeted organometallic iridium( iii ) complexes as novel theranostic agents. Chem Commun. 2017;53(40):5523-6.
dc.identifier.issn	1359-7345
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/23891
dc.description.abstract	A novel somatostatin receptor-targeted anticancer agent based on the conjugation of a highly cytotoxic and luminescent cyclometalated iridium(iii) complex to tumor-targeting vectors based on octreotide peptide has been described, and its potential for targeted theranostic applications has been demonstrated.
dc.language.iso	eng
dc.publisher	ROYAL SOC CHEMISTRY
dc.rights	Atribución/Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional
dc.rights.uri	https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es	*
dc.title	Somatostatin receptor-targeted organometallic iridium(III) complexes as novel theranostic agents
dc.type	info:eu-repo/semantics/article
dc.identifier.pmid	28466888
dc.relation.publisherversion	https://xlink.rsc.org/?DOI=C7CC01946G
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.identifier.doi	10.1039/c7cc01946g
dc.journal.title	Chemical Communications
dc.identifier.essn	1364-548X